Decreased Relapse, Mortality Rates With Rituximab in Acquired Thrombotic Thrombocytopenic Purpura
Researchers conducted a meta-analysis of 9 studies in patients receiving either rituximab or conventional treatment for TTP.
Thrombotic Thrombocytopenic Purpura
Managing Neonatal Thrombocytopenia of Alloimmune Origin
A French working group developed a treatment algorithm for diagnosis and treatment of neonatal thrombocytopenia of suspected or confirmed alloimmune origin.
Cablivi Approved for Acquired Thrombotic Thrombocytopenic Purpura
First FDA-approved therapy specifically indicated for the treatment of aTTP
Lower Platelet Transfusion Threshold in Neonates With Thrombocytopenia May Reduce Mortality
Researchers attempted to identify the appropriate platelet count transfusion threshold in preterm infants with severe thrombocytopenia.
Caplacizumab Cuts Time to Platelet Count Normalization in aTTP Patients
The HERCULES (NCT02553317) study included 145 patients with aTTP who were randomized to receive either caplacizumab 10mg or placebo in conjunction with plasma exchange and immunosuppression.
Next post in Thrombotic Disorders
